![Harout Semerjian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Harout Semerjian
Vermögen: 2 965 $ am 31.12.2025
Profil
Harout Semerjian currently works at Geron Corp., as President, Chief Executive Officer & Director from 2025 and Biotechnology Innovation Organization, as Director from 2023.
Mr. Semerjian also formerly worked at Immunomedics, Inc., as President, Chief Executive Officer & Director in 2020, GlycoMimetics, Inc., as President, Chief Executive Officer & Director from 2021 to 2025, Ipsen SA, as Chief Commercial Officer & Executive VP from 2018 to 2020, and Ipsen Pharma SAS, as Chief Commercial Officer & Executive VP from 2018 to 2020.
Mr. Semerjian received his Masters Business Admin degree from Queen's University, Masters Business Admin degree from Cornell University, and undergraduate degree from Lebanese American University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0 % | 07.02.2025 | 250 ( 0 % ) | 2 965 $ | 31.12.2025 |
Aktuelle Nachrichten zu Harout Semerjian
Aktive Positionen von Harout Semerjian
| Unternehmen | Position | Beginn |
|---|---|---|
| GERON CORPORATION | Vorstandsvorsitzender | 07.08.2025 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Direktor/Vorstandsmitglied | 01.10.2023 |
Ehemalige bekannte Positionen von Harout Semerjian
| Unternehmen | Position | Ende |
|---|---|---|
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Vorstandsvorsitzender | 21.02.2025 |
| IMMUNOMEDICS, INC. | Vorstandsvorsitzender | 27.05.2020 |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 30.04.2020 |
| IPSEN | Corporate Officer/Principal | 01.04.2020 |
Ausbildung von Harout Semerjian
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. Develops drugs for the treatment of cancer | |
Geron Corp.
 Geron Corp. BiotechnologyHealth Technology Discovers and develops therapeutic products for cancer | Health Technology |
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Lebanese American University
 Lebanese American University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
